NovaBridge officer exercises RSUs for 339,372 shares

NovaBridge Biosciences officer converts restricted share units into ordinary shares and ADSs as multi-year equity awards vest.

Rhea-AI Filing Summary

NovaBridge Biosciences (NBP) reports that Chief Business Development Officer Cao Sean Wuxiong exercised previously granted restricted share units on September 3, 2026, converting 147,553 RSUs into 339,372 Ordinary Shares represented by American Depositary Shares. These RSUs come from grants of 408,933 units in 2025 and 181,280 units in 2026 that vest over four years. No trades are reported under a Rule 10b5-1 trading plan.

Insider Trade Summary

147,553 shares exercised/converted

Exercise 4 txns

Insider Cao Sean Wuxiong

Role Chief Bus. Development Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units F3, F5, F1	102,233	$0.00	$0.00
Exercise	Restricted Share Units F3, F6, F1	45,320	$0.00	$0.00
Exercise	Ordinary Shares F1, F2, F3	235,136	--	--
Exercise	Ordinary Shares F1, F4, F3	104,236	--	--

Holdings After Transaction: Restricted Share Units — 442,660 contracts (Direct); Ordinary Shares — 374,445 shares (Direct)

Footnotes (6)

1. F1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
2. F2. Reported securities are represented by 102,233 ADSs
3. F3. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
4. F4. Reported securities are represented by 45,320 ADSs.
5. F5. On September 3, 2025, the Reporting Person was granted 408,933 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month.
6. F6. On June 22, 2026, the Reporting Person was granted 181,280 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on September 3, 2026 and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month.

Key Figures

RSUs exercised: 147,553 units Ordinary Shares received: 339,372 shares ADSs from first RSU block: 102,233 ADSs +4 more

7 metrics

RSUs exercised 147,553 units Restricted share units converted on September 3, 2026

Ordinary Shares received 339,372 shares Shares issued upon RSU conversion on September 3, 2026

ADSs from first RSU block 102,233 ADSs Reported securities represented by 102,233 ADSs from one RSU grant

ADSs from second RSU block 45,320 ADSs Reported securities represented by 45,320 ADSs from a later RSU grant

2025 RSU grant size 408,933 units RSUs granted on September 3, 2025 vesting over four years

2026 RSU grant size 181,280 units RSUs granted on June 22, 2026 vesting over four years

ADS to Ordinary Share ratio 10 ADSs represent 23 Ordinary Shares Representation ratio for NovaBridge Biosciences Ordinary Shares

Key Terms

American Depositary Shares, restricted stock unit, contingent right

3 terms

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares ("ADS")."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

restricted stock unit financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one ADS."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one ADS."

FAQ

What insider equity transaction did NBP report for Cao Sean Wuxiong?

NBP reported that Cao Sean Wuxiong exercised 147,553 restricted share units on September 3, 2026, receiving 339,372 Ordinary Shares represented by American Depositary Shares as part of his equity compensation vesting.

How many NovaBridge Biosciences RSUs did the officer convert into shares?

On September 3, 2026, the officer converted a total of 147,553 RSUs into NovaBridge Biosciences equity, consisting of 102,233 units in one block and 45,320 units in another.

How many NovaBridge Biosciences Ordinary Shares were received from the RSU exercises?

The RSU exercises resulted in the officer receiving 339,372 Ordinary Shares of NovaBridge Biosciences, made up of 235,136 shares in one transaction and 104,236 shares in another.

What is the ADS to Ordinary Share ratio for NBP in this filing?

Each American Depositary Share for NBP represents 23 Ordinary Shares for every 10 ADSs. The filing notes that the Ordinary Shares may be represented by ADSs using this ratio.

What RSU grants to the NovaBridge Biosciences officer are described?

The officer was granted 408,933 RSUs on September 3, 2025 and 181,280 RSUs on June 22, 2026. Each grant vests over four years, with one-fourth vesting first and the remaining units vesting quarterly over 12 quarters.

Were the NBP insider transactions made under a Rule 10b5-1 plan?

No. The filing indicates that the reported transactions were not made pursuant to a Rule 10b5-1 trading plan, so there is no pre-arranged trading plan status associated with these exercises.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 05:51 PM Accepted by SEC EDGAR 09/08/2026 - 05:51 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cao Sean Wuxiong

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Bus. Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	09/03/2026		M		235,136(2)	A	(3)	270,209	D
Ordinary Shares(1)	09/03/2026		M		104,236(4)	A	(3)	374,445	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(3)	09/03/2026		M			102,233	(5)	(5)	Ordinary Shares(1)	102,233	$0	306,700	D
Restricted Share Units	(3)	09/03/2026		M			45,320	(6)	(6)	Ordinary Shares(1)	45,320	$0	135,960	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Reported securities are represented by 102,233 ADSs

3. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.

4. Reported securities are represented by 45,320 ADSs.

5. On September 3, 2025, the Reporting Person was granted 408,933 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month.

6. On June 22, 2026, the Reporting Person was granted 181,280 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on September 3, 2026 and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month.

	/s/ Kyler Lei as attorney-in-fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)